Mechanisms of zidovudine-induced mitochondrial toxicity and myopathy

Pharmacology

Volumn 82, Issue 2, 2008, Pages 83-88

  Scruggs, Erin R ^a   Dirks Naylor, Amie J ^a  

^a WINGATE UNIVERSITY   (United States)

Author keywords

Apoptosis; Azidothymidine; Oxidative stress; Skeletal muscle; Zidovudine

Indexed keywords

CARNITINE; DNA DIRECTED DNA POLYMERASE GAMMA; MITOCHONDRIAL DNA; ZIDOVUDINE;

APOPTOSIS; CANCER THERAPY; DRUG EFFICACY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MITOCHONDRIAL ENERGY TRANSFER; MITOCHONDRIAL TOXICITY; MYOPATHY; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

ANTI-HIV AGENTS; APOPTOSIS; CARNITINE; DNA, MITOCHONDRIAL; DNA-DIRECTED DNA POLYMERASE; HUMANS; MITOCHONDRIA; MUSCULAR DISEASES; OXIDATIVE STRESS; ZIDOVUDINE;

EID: 49749119530     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000134943     Document Type: Review

References (45)

1. Georges B, Galland S, Rigault C, Le Borgne F, Demarquoy J: Beneficial effects of L-carnitine in myoblastic C2C12 cells: interaction with zidovudine. Biochem Pharmacol 2003;65:1483-1488.
2. Dalakas MC, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL: Mitochondrial myopathy caused by long-term zidovudine therapy. N Engl J Med 1990;322:1098-1105.
3. Owczarek J, Jasinska M, Orszulak-Michalak D: Drug-induced myopathies: an overview of the possible mechanisms. Pharmacol Rep 2005;57:23-34.
4. Masanes F, Barrientos A, Cebrian M, Pedrol E, Miro O, Casademont J, Grau JM: Clinical, histological and molecular reversibility of zidovudine myopathy. J Neurol Sci 1998;159:226-228.
5. Arnaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA: Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991;337:508-510.
6. Lewis W, Copeland WC, Day BJ: Mitochondrial DNA depletion, oxidative stress, and mutation: mechanisms of dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 2001;81:777-790.
7. Tolomeo M, Mancuso S, Todaro M, Stassi G, Catalano M, Arista S, Cannizzo G, Barbusca E, Abbadessa V: Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy. J Clin Pathol 2003;56:147-151.
8. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV, Montaner JS: Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-820.
9. Martin JL, Brown CE, Matthews-Davis N, Reardon JE: Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-2749.
10. Lynx MD, McKee EE: 3′-Azido-3′-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria. Biochem Pharmacol 2006;72:239-243.
11. Rylova SN, Albertioni F, Flygh G, Eriksson S: Activity profiles of deoxynucleoside kinases and 5′-nucleotidases in cultured adipocytes and myoblastic cells: insights into mitochondrial toxicity of nucleoside analogs. Biochem Pharmacol 2005;69:951-960.
12. Lebrecht D, Deveaud C, Beauvoit B, Bonnet J, Kirschner J, Walker UA: Uridine supplementation antagonizes zidovudine-induced mitochondrial myopathy and hyperlactatemia in mice. Arthritis Rheum 2008;58:318-326.
13. Modica-Napolitano JS: AZT causes tissue-specific inhibition of mitochondrial bioenergetic function. Biochem Biophys Res Commun 1993;194:170-177.
14. Yamaguchi T, Katoh I, Kurata S: Azidothymidine causes functional and structural destruction of mitochondria, glutathione deficiency and HIV-1 promoter sensitization. Eur J Biochem 2002;269:2782-2788.
15. Cazzalini O, Lazze MC, Iamele L, Stivala LA, Bianchi L, Vaghi P, Cornaglia A, Calligaro A, Curti D, Alessandrini A, Prosperi E, Vannini V: Early effects of AZT on mitochondrial functions in the absence of mitochondrial DNA depletion in rat myotubes. Biochem Pharmacol 2001;62:893-902.
16. de la Asuncion JG, del Olmo ML, Sastre J, Millan A, Pellin A, Pallardo FV, Vina J: AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria: prevention by antioxidant vitamins. J Clin Invest 1998;102:4-9.
17. Wheeler S, Maxwell-Bawden A, Herb RA, Gallagher GE, Coast JR: Zidovudine-induced diaphragmatic contractile dysfunction: impact of an antioxidant diet. Respirology 2005;10:171-176.
18. Linnane AW, Degli Esposti M, Generowicz M, Luff AR, Nagley P: The universality of bioenergetic disease and amelioration with redox therapy. Biochim Biophys Acta 1995;1271:191-194.
19. Rosenfeldt FL, Mijch A, McCrystal G, Sweeney C, Pepe S, Nicholls M, Dennett X: Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. Int J STD AIDS 2005;16:827-829.
20. Dalakas MC, Leon-Monzon ME, Bernardini I, Gahl WA, Jay CA: Zidovudine-induced mitochondrial myopathy is associated with muscle carnitine deficiency and lipid storage. Ann Neurol 1994;35:482-487.
21. Semino-Mora MC, Leon-Monzon ME, Dalakas MC: Effect of L-carnitine on the zidovudine-induced destruction of human myotubes. I. L-carnitine prevents the myotoxicity of AZT in vitro. Lab Invest 1994;71:102-112.
22. Kokoszka JE, Coskun P, Esposito LA, Wallace DC: Increased mitochondrial oxidative stress in the Sod2 (+/-) mouse results in the age-related decline of mitochondrial function culminating in increased apoptosis. Proc Natl Acad Sci USA 2001;98:2278-2283.
23. Liu CY, Lee CF, Hong CH, Wei YH: Mitochondrial DNA mutation and depletion increase the susceptibility of human cells to apoptosis. Ann NY Acad Sci 2004;1011:133-145.
24. Ratan RR, Murphy TH, Baraban JM: Oxidative stress induces apoptosis in embryonic cortical neurons. J Neurochem 1994;62:376-379.
25. Unger RH, Orci L: Lipoapoptosis: its mechanism and its diseases. Biochim Biophys Acta 2002;1585:202-212.
26. Mirabella M, Di Giovanni S, Silvestri G, Tonali P, Servidei S: Apoptosis in mitochondrial encephalomyopathies with mitochondrial DNA mutations: a potential pathogenic mechanism. Brain 2000;123(pt 1):93-104.
27. Ikezoe K, Nakagawa M, Yan C, Kira J, Goto Y, Nonaka I: Apoptosis is suspended in muscle of mitochondrial encephalomyopathies. Acta Neuropathol (Berl) 2002;103:531-540.
28. Umaki Y, Mitsui T, Endo I, Akaike M, Matsumoto T: Apoptosis-related changes in skeletal muscles of patients with mitochondrial diseases. Acta Neuropathol (Berl) 2002;103:163-170.
29. Formichi P, Battisti C, Bianchi S, Cardaioli E, Federico A: Evidence of apoptosis via TUNEL staining in muscle biopsy from patients with mitochondrial encephaloneuromyopathies. J Submicrosc Cytol Pathol 2003;35:29-34.
30. Sandri M, Carraro U, Podhorska-Okolov M, Rizzi C, Arslan P, Monti D, Franceschi C: Apoptosis, DNA damage and ubiquitin expression in normal and mdx muscle fibers after exercise. FEBS Lett 1995;373:291-295.
31. Adams V, Jiang H, Yu J, Mobius-Winkler S, Fiehn E, Linke A, Weigl C, Schuler G, Hambrecht R: Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol 1999;33:959-965.
32. Belizario JE, Lorite MJ, Tisdale MJ: Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001;84:1135-1140.
33. Alway SE, Degens H, Krishnamurthy G, Chaudhrai A: Denervation stimulates apoptosis but not Id2 expression in hindlimb muscles of aged rats. J Gerontol A Biol Sci Med Sci 2003;58:687-697.
34. Allen DL, Linderman JK, Roy RR, Bigbee AJ, Grindeland RE, Mukku V, Edgerton VR: Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Am J Physiol 1997;273:C579-C587.
35. Alway SE, Degens H, Krishnamurthy G, Smith CA: Potential role for Id myogenic repressors in apoptosis and attenuation of hypertrophy in muscles of aged rats. Am J Physiol Cell Physiol 2002;283:C66-C76.
36. Dirks A, Leeuwenburgh C: Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 2002;282:R519-R527.
37. Dirks AJ, Leeuwenburgh C: Aging and life-long calorie restriction result in adaptations of skeletal muscle apoptosis repressor, apoptosis-inducing factor, X-linked inhibitor of apoptosis, caspase-3, and caspase-12. Free Radic Biol Med 2004;36:27-39.
38. Dirks AJ, Jones KM: Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291:C1208-C1212.
39. Lee MC, Wee GR, Kim JH: Apoptosis of skeletal muscle on steroid-induced myopathy in rats. J Nutr 2005;135:S1806-S1808.
40. Collier AC, Helliwell RJ, Keelan JA, Paxton JW, Mitchell MD, Tingle MD: 3′-azido-3′-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol Appl Pharmacol 2003;192:164-173.
41. Falchetti A, Franchi A, Bordi C, Mavilia C, Masi L, Cioppi F, Recenti R, Picariello L, Marini F, Del Monte F, Ghinoi V, Martineti V, Tanini A, Brandi ML: Azidothymidine induces apoptosis and inhibits cell growth and telomerase activity of human parathyroid cancer cells in culture. J Bone Miner Res 2005;20:410-418.
42. Sun YQ, Guo TK, Xi YM, Chen C, Wang J, Wang ZR: Effects of AZT and RNA-protein complex (FA-2-b-beta) extracted from Liang Jin mushroom on apoptosis of gastric cancer cells. World J Gastroenterol 2007;13:4185-4191.
43. Ji HJ, Rha SY, Jeung HC, Yang SH, An SW, Chung HC: Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss. Breast Cancer Res Treat 2005;93:227-236.
44. Zhou FX, Liao ZK, Dai J, Xiong J, Xie CH, Luo ZG, Liu SQ, Zhou YF: Radiosensitization effect of zidovudine on human malignant glioma cells. Biochem Biophys Res Commun 2007;354:351-356.
45. Purevjav E, Nelson DP, Varela JJ, Jimenez S, Kearney DL, Sanchez XV, Defreitas G, Carabello B, Taylor MD, Vatta M, Shearer WT, Towbin JA, Bowles NE: Myocardial Fas Ligand Expression Increases Susceptibility to AZT-Induced Cardiomyopathy. Cardiovasc Toxicol 2007;7:255-263.